Chronological age is a risk factor for SARS-CoV-2 infection and severe COVID-19. Previous findings indicate that epigenetic age could be altered in viral infection. However, the epigenetic aging in COVID-19 has not been well studied. In this study, DNA methylation of the blood samples from 232 healthy individuals and 413 COVID-19 patients is profiled using EPIC methylation array. Epigenetic ages of each individual are determined by applying epigenetic clocks and telomere length estimator to the methylation profile of the individual. Epigenetic age acceleration is calculated and compared between groups. We observe strong correlations between the epigenetic clocks and individual’s chronological age ($r > 0.8$, $p < 0.0001$). We also find the increasing acceleration of epigenetic aging and telomere attrition in the sequential blood samples from healthy individuals and infected patients developing non-severe and severe COVID-19. In addition, the longitudinal DNA methylation profiling analysis find that the accumulation of epigenetic aging from COVID-19 syndrome could be partly reversed at late clinic phases in some patients. In conclusion, accelerated epigenetic aging is associated with the risk of SARS-CoV-2 infection and developing severe COVID-19. In addition, the accumulation of epigenetic aging from COVID-19 may contribute to the post-COVID-19 syndrome among survivors.
The ongoing pandemic of coronavirus disease 2019 (COVID-19) due to severe acute respiratory syndrome-corona virus 2 (SARS-CoV-2) infection is a rapidly developing global emergency which already claimed over 170 million cases and 3.8 million lives worldwide as of June 13rd, 2021 (WHO Coronavirus Situation Report, 2021). The incidence of severity and death in COVID-19 patients has been reported to increase with age.2–5 Chronological age has been proven to be one of the major risk factors for developing severe COVID-19 and death6, and this risk is independent of other age-related comorbidities like diabetes, cardiovascular diseases, or obesity. Therefore, understanding the biological aging of COVID-19 in severe cases versus non-severe patients could be quite useful to model and predict the disease progression with other laboratory assays4.

Aging is a biological process related to diseases and mortality. The biological process in aging is reflected by molecular hallmarks, which include epigenetic modifications and telomere attrition6–8. DNA methylation correlates with aging process and can be used to estimate epigenetic aging across tissues.2–14 The deviation between DNA methylation age (DNAm age) and chronological age has been proposed as a biomarker for aging and has been related to risk and survival outcomes in age-related diseases.15,16 Previous work showed that the epigenetic landscape of host cell is altered during HIV17–19 and coronavirus19–23 infection, including SARS-CoV-2. In addition, telomere attrition in leukocytes is another hallmark of aging and associated with increased risk of aging-related diseases and human life span24–26, and a DNAm-based telomere length estimator (DNAm TL) has been developed.27 Interestingly, telomere length and the epigenetic clock do not correlate with one another, suggesting that DNAm age and TL measure different aspects of biological aging.28,29 Recently, epigenetic age at the moment of the infection has been reported to be associated with COVID-19.30–32 However, little is known about the epigenetic aging during SARS-CoV-2 infection and in COVID-19 survivors and whether this factor might help predict the risk of developing severe COVID-19.

In this study, we estimated the epigenetic age of the whole blood in COVID-19 patients and healthy individuals using the previously established epigenetic clocks (Hannum, Horvath, PhenoAge, skinHorvath and GrimAge clocks)12,33–36 and telomere length estimator.27 We defined epigenetic age acceleration for each case by comparing the individual’s epigenetic age with chronological age to assess whether the accelerated or dysfunctional epigenetic aging is associated with SARS-CoV-2 infection and the severity of COVID-19 syndrome.

**Results**

Assessment of epigenetic age in COVID-19 patients. To study epigenetic aging in the whole blood and its correlation with non-severe and severe COVID-19, we conducted a genome-wide DNA methylation study on whole blood collected from 232 healthy individuals, 194 non-severe and 213 severe COVID-19 patients in the combined set to calculate their DNAm age and TL using five different epigenetic clocks and DNAm TL estimator. The COVID-19 patients were not significantly different from the healthy individuals in terms of age and sex (Supplementary Table 1).

We calculated the Pearson correlation coefficient among individual chronological age, epigenetic clocks and DNAm TL in the combined set of samples. As shown in Fig. 1, all clocks had a strong correlation with the chronological age in the whole set and each sample group (r > 0.8, p < 0.0001), though the PhenoAge clock showed weaker correlations with chronological age in the severe COVID-19 group (r = 0.73, p < 0.0001). In addition, all clocks were strongly correlated with one another in all groups (r > 0.8, p < 0.0001; Fig. 1 and Supplementary Fig. 1), except that PhenoAge clock showed weaker correlations with other clocks in the severe COVID-19 group (r = 0.73 ~ 0.77, p < 0.0001). DNAm TL was negatively correlated with chronological and DNAm ages in the whole set and all groups (r = −0.59 ~ −0.90, p < 0.0001; Fig. 1). Interestingly, DNAm TL showed a stronger linear correlation with DNAm ages compared to chronological age (Fig. 1 and Supplementary Fig. 2).

Accelerated epigenetic aging in SARS-CoV-2 infection. We initially assessed the DNAm ages and TLs of the blood samples and found an older DNAm age in the COVID-19 patients for Horvath, Hannum, skinHorvath and GrimAge clocks compared to the healthy individuals (p < 0.05; Supplementary Fig. 3). To adjust for the bias due to individual chronological age, we calculated epigenetic age acceleration for each sample. Individuals with COVID-19 were estimated to have significant DNAm age acceleration for Hannum, PhenoAge, skinHorvath and GrimAge clocks and significant DNAm TL attrition acceleration compared with healthy individuals (all p < 0.0001; Supplementary Fig. 4). The same phenomena were observed in the young (age < 50) and old (age ≥ 50) populations (Supplementary Fig. 5). Together, we found an accelerated epigenetic aging in patients with SARS-CoV-2 infection.

Accelerated epigenetic aging and risk of developing severe COVID-19. Next, we analyzed the association of COVID-19 severity with epigenetic aging. We found individuals with severe COVID-19 had significant DNAm age acceleration for all epigenetic clocks and DNAm TL attrition acceleration compared with healthy individuals (all p < 0.0001; Fig. 2). In addition, severe COVID-19 patients had significant DNAm age acceleration for Horvath, Hannum, PhenoAge and GrimAge clocks and significant DNAm TL attrition acceleration compared with non-severe COVID-19 patients (all p < 0.05; Fig. 2). Moreover, non-severe COVID-19 patients had significant DNAm age acceleration for Horvath, Hannum, skinHorvath and GrimAge clocks and significant DNAm TL attrition acceleration compared with healthy individuals (all p < 0.05; Fig. 2). Among the five epigenetic clocks, the statistical difference in the pairwise test for GrimAge clock was most significant. In addition, we found that COVID-19 patients developing pneumonia had significantly accelerated epigenetic aging compared with those not developing pneumonia (Supplementary Fig. 6). Together, we found an increasing acceleration of epigenetic aging in the sequential samples of healthy, non-severe and severe groups.

Dynamic acceleration of epigenetic aging across COVID-19 disease phases. To explore the role of COVID-19 in epigenetic age acceleration, we analyzed the dynamic acceleration of epigenetic age across COVID-19 disease phases in the Bernardes et al’s longitudinal cohort37 with six COVID-19 cases and six uninfected controls. Clinical disease phases were defined based on inflammatory markers and ventilation needs, which reflected temporal disease severity and distinguish between incremental and recovering disease stages, according to the WHO ordinal scale described by Bernardes et al.37. We assessed the DNAm ages and TLs of the samples collected from each disease phase and found an increasing acceleration of epigenetic aging at the initial phases of COVID-19, and this age acceleration could be partly reversed at later phases (Fig. 3a). Specifically, we found an increasing acceleration of Horvath age at the initial two disease phases and this acceleration was partly reversed in the upcoming convalescence phase. Similarly,
Hannum and PhenoAge clocks were accelerated at the initial stage of incremental and critical disease phase and reversed in the upcoming complicated and convalescence phases. In addition, an increasing attrition acceleration of DNAm age at the initial two disease phases was found to be partly reversed in the upcoming convalescence phase, although the differences between every two phases were not statistically significant.

Furthermore, we tracked the dynamic changes of DNAm ages and TLs during the clinical disease phases in individual patients and observed similar result to the group-wise comparison. The accelerated DNAm ages at initial phases were partly reversed at the later phases in some COVID-19 patients by using the five epigenetic clocks, while the reversible outcome of accelerated attrition of DNAm TL from initial to later phases was found only in one patient (Fig. 3b). Therefore, we speculated that COVID-19 syndrome might accelerate epigenetic aging in SARS-CoV-2 infected patients, and this process would be partly reversible in the clinical disease phases.

**Discussion**

In this study, we took advantage of prior indication that epigenetic age could be altered in the presence of viral infections\textsuperscript{17,20,38} and from the fact that shorter telomeres have been associated with the risk of developing COVID-19 with worse outcomes\textsuperscript{32}. We used five epigenetic clocks and one

---

**Fig. 1 Assessment of epigenetic clocks and DNA methylation-based telomere length estimator in patient cohorts. a-e** Correlation of chronological age with five epigenetic clocks (a Horvath; b Hannum; c PhenoAge; d skinHorvath; e GrimAge) and DNA methylation-based telomere length (f TL) estimator in the peripheral blood from 232 healthy individuals, 194 non-severe and 213 severe COVID-19 patients. g Heatmap presents the matrix of Pearson correlation coefficients among chronological age, DNAm ages determined by each epigenetic clock, and DNAm TL in the whole, healthy, non-severe and severe sets. Source data are provided as a Source Data file.
telomere length estimator to determine the epigenetic age of the whole blood in COVID-19 patients and healthy individuals. We observed strong correlation of the epigenetic clocks with the chronological age and increasing acceleration of epigenetic aging in the blood samples of healthy individuals and COVID-19 patients. Our epigenetic study with consistent findings from different epigenetic clocks provides evidence for the association of accelerated epigenetic aging with the risk of SARS-CoV-2 infection and developing severe COVID-19. In addition, we found a reversible influence of COVID-19 syndrome on epigenetic aging in some COVID-19 patients with the longitudinal DNA methylation profiling analysis. Overall, these findings suggest that COVID-19 may perturb the epigenetic clock and telomere length. Although the epigenetic clocks and telomere length are known as independent28,29, DNAm aging was paralleled by a telomere shortening in all the observations.

![Fig. 2 Accelerated epigenetic aging in non-severe and severe COVID-19 patients.](image)

Distribution of DNAm age acceleration (a–e, five epigenetic clocks) and telomere attrition acceleration (f, TL) in the peripheral blood from 232 healthy individuals, 194 non-severe and 213 severe COVID-19 patients. The y-axis shows the epigenetic age acceleration after adjusting for cell-type fractions (i.e., residual of regressing the epigenetic age acceleration on cell-type fractions). The p value for each t-test is shown above the corresponding line. In the box plots, the lower and upper hinges indicate the 25th and 75th percentiles, and the black line within the box marks the median value. The whiskers extend from the hinges to the largest and smallest values no further than 1.5× inter-quartile range from the hinges, and the points beyond the end of whiskers indicate outliers. Source data are provided as a Source Data file.

![Fig. 3 Epigenetic aging across COVID-19 disease phases.](image)

a Acceleration of DNAm aging (five epigenetic clocks) and telomere attrition of the blood samples collected from uninfected control and patients at each clinical disease phase. b Dynamic change of epigenetic age acceleration in each individual across COVID-19 disease phases. The p value for each t-test is shown above the corresponding line. In the box plots, the lower and upper hinges indicate the 25th and 75th percentiles, and the black line within the box marks the median value. The whiskers extend from the hinges to the largest and smallest values no further than 1.5× inter-quartile range from the hinges, and the points beyond the end of whiskers indicate outliers. Source data are provided as a Source Data file.
DNA methylation-based estimator of telomere length was shown to have a relatively weak correlation with PCR-based telomere length that is recognized as an accurate quantification. Therefore, PCR assays are needed to validate the correlation between telomere length and COVID-19. Mongelli et al. applied PCR assay to quantify telomere length and found a telomere shortening in the post-COVID-19 survivors. Although some of our findings could be supported by Mongelli, the association of telomere attrition with severe COVID-19 and dynamic change of telomere length across disease phases need to be confirmed in a longitudinal cohort with PCR assays.

Epigenetic changes have been reported to be associated with the SARS-CoV-2 infection and unfavorable COVID-19 outcomes, including the methylation regulation of Angiotensin Converting Enzyme 2 (ACE2)23, interferon-related pathways23, and immune response genes23,41. Considering the DNA methylation changes in SARS-CoV-2 infection that may affect the expression of metabolic process and epigenetic aging of COVID-19, a further question could be whether the accelerated epigenetic aging exists before the first viral contact, worsening progressively up or coming back to normal during the convalescent phases and post-COVID-19 period. Our analysis of epigenetic clocks and telomere shortening indicates an increasing age acceleration at the initial phases of COVID-19 and this could be partly reversed at later phases. We speculated that COVID-19 syndrome might accelerate epigenetic aging in SARS-CoV-2-infected patients based on these findings. Our longitudinal DNA methylation profiling analysis indicates that the influence of COVID-19 syndrome on epigenetic aging in peripheral blood could be reversed in some patients. However, additional experiments are necessary to validate these findings and elucidate the underlying mechanism.

In the current study, we found accelerated epigenetic aging could serve as a predicting biomarker for severe COVID-19 that requires hospitalization with increased mortality. However, a recent study found that the association of accelerated epigenetic aging with severe COVID-19 varied among different epigenetic clocks and datasets, which might be attributed to the small sample size in some datasets, unspecified severity of COVID-19 cases, and the different estimation method of age acceleration. Interestingly, the difference between severe COVID-19 patients and other individuals in the GrimAge clock was most significant among the five epigenetic clocks in our cohort. The strong stratification in the severity of COVID-19 may come from the correlation between GrimAge clock and smoking-associated changes that were shown to be a prognostic factor for severe illness and mortality in COVID-19 patients23,45.

Of note, there is a lack of molecular biomarkers potentially valuable in monitoring post-COVID-19 syndrome that will require long-term assistance among the millions of COVID-19 survivors. Based on our findings, we speculate that the accumulation of epigenetic aging and telomere attrition after SARS-CoV-2 infection might contribute to the post-COVID-19 syndrome, and irreversible epigenetic aging might be served as a biomarker for the risk of developing post-COVID-19 syndrome. It is noteworthy that this study has some limitations. First, our longitudinal analysis indicates the recovery of accelerated epigenetic aging occurred in some patients, though none of the post-COVID-19 survivors with post-COVID-19 syndrome was included in our study. In addition, the limited cases were included in the longitudinal analysis, and the findings require validation in a larger and more diverse longitudinal cohort. Next, the causal relationship between COVID-19 and accelerated epigenetic aging remains unanswered in the current study. A longitudinal cohort with sustaining follow-up from the time point before SARS-CoV-2 infection to post-COVID-19 phase would be helpful to address this question, though it would be challenging to conduct a study with this design. A long-term follow-up of crowdsourced populations57,48 may facilitate the longitudinal research and provide valuable evidence. Furthermore, we cannot rule out the potential confounding effects of chronic inflammation, oxidative stress in respiratory failure and prior medication use. Finally, the application of epigenetic aging markers in predicting COVID-19 outcomes is limited by the cost and accessibility of methylation arrays. However, representative age-related CpG methylation changes could be applied by using qPCR-based assays and pyrosequencing59,49,50. We anticipate that epigenetic aging-related markers would be useful to predict disease progression in COVID-19 with other laboratory assays61,62.
Cell composition estimation. Based on the accumulating evidence reporting the change of immune cell composition in severely COVID-19 patients, we estimated the cell counts with the ‘mefﬁl’ tool85 and performed cell composition adjustment to control the impact on epigenetic age acceleration estimation.

Statistical methods. The correlation among DNAm age, DNAm TL and chronological age of the samples was calculated with the Pearson correlation coefﬁcient. A linear regression model was applied to determine the relationship between the epigenetic age and chronological age at the time of sample collection. All statistical analysis was performed using R Statistical Software (version 3.6.1). P values < 0.05 were considered statistically signiﬁcant.

Reporting summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.

Data availability

The complete DNA methylation raw data of the severe and non-severe COVID-19 cases have been deposited on the GEO repository under accession number GSE168739, and the clinical outcomes of these cases are not publicly available for data privacy but are available from Dr. Manel Esteller (mesteller@carrerasresearch.org) upon request for research collaboration. The timeframe for response to data access requests is 30 days. There are no restrictions on the reuse of data. In addition, the DNA methylation raw data of the longitudinal cohort and healthy individuals analyzed in this study were available at GEO with identiﬁers of GSE161678, GSE149318, GSE123914, GSE145254, GSE181144 and GSE141682. Source data are provided with this paper.

Received: 27 July 2021; Accepted: 30 March 2022; Published online: 19 April 2022

References

1. WHO. 2021. Coronavirus Situation Report. https://cdr.who.int/media/docs/default-source/searo/whe/coronavirus19/sear-weekly-reports/sear-weekly-situation-report-23-2021.pdf?sfvrsn=55403bf_5
2. Gupta, S. et al. Factors associated with death in critically ill patients with coronavirus disease 2019 in the US. JAMA Intern Med 180, 1436–1447 (2020).
3. Levin, A. T. et al. Assessing the age speciﬁcity of infection fatality rates for COVID-19: systematic review, meta-analysis, and public policy implications. Eur. J. Epidemiol. 35, 1122–1138 (2020).
4. Chen, Y. et al. Epidemiological feature, viral shedding, and antibody seroconversion among asymptomatic SARS-CoV-2 carriers and symptomatic/ presymptomatic COVID-19 patients. J. Infect. Public Health 14, 845–851 (2021).
5. Liu, Y. et al. Association between age and clinical characteristics and outcomes of COVID-19. Eur. Respir. J. 55, (2020).
6. Zhou, F. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet 395, 1054–1062 (2020).
7. Mueller, A. L., McNamara, M. S. & Sinclair, D. A. Why does COVID-19 change of immune cell composition in severe COVID-19 patients,37,63,64 we estimated adjustment to control the impact on epigenetic age acceleration estimation.
8. Bell, C. G. et al. DNA methylation aging clocks: challenges and recommendations. Genome Biol. 20, 249 (2019).
9. Wang, T. et al. Dysfunctional epigenetic aging of the normal colon and colorectal cancer risk. Clin. Epigenetics 12, 5 (2020).
10. Yu, M., Hazeldon, W. D., Luebeck, G. E. & Grady, W. M. Epigenetic aging: more than just a clock when it comes to cancer. Cancer Res. 80, 367–374 (2020).
11. Esteban-Cantos, A. et al. Epigenetic age acceleration changes 2 years after antiretroviral therapy initiation in adults with HIV: a substudy of the NEAT001/ANRSi43 randomized trial. Lancet HIV 8, e197–197e205 (2021).
12. Horvath, S. & Levine, A. J. HIV-1 infection accelerates age according to the epigenetic clock. J. Infect. Dis. 212, 1563–1573 (2015).
13. Horvath, S. et al. Peripherally acquired HIV infection accelerates epigenetic aging in South African adolescents. AIDS 32, 1465–1474 (2018).
14. Corley, M. J. et al. Genome-wide DNA methylation proﬁling of peripheral blood reveals an epigenetic signature associated with severe COVID-19. J. Leukoc. Biol., (2021).
15. Schäfer, A. & Baric, R. S. Epigenetic Landscape during Coronavirus Infection. Pathogens 6, (2017).
16. Menachery, V. D. et al. MERS-CoV and H5N1 inﬂuenza virus antagonize antigen presentation by altering the epigenetic landscape. Proc. Natl. Acad. Sci. USA 115, E1012–E1021E1021 (2018).
17. Castro de Moura, M. et al. Epigenome-wide association study of COVID-19 severity with respiratory failure. ElBioMedicine 66, 103339 (2021).
18. Arbeek, K. G. et al. Association of leukocyte telomere length with mortality among adult participants in 3 longitudinal studies. JAMA Netw. Open 3, e200203 (2020).
19. Haycock, P. C. et al. Leucocyte telomere length and risk of cardiovascular disease: systematic review and meta-analysis. BMJ 349, g2227 (2014).
20. Demel, K. et al. Determinants of telomere length across human tissues. Science 369, (2020).
21. Lu, A. T. et al. DNA methylation-based estimator of telomere length. Aging (Albany NY) 11, 5895–5929 (2019).
22. Marion, R. E. et al. The epigenetic clock and telomere length are independently associated with chronological age and mortality. Int J. Epidemiol. 45, 424–432 (2018).
23. Banszerus, V. L., Vetter, V. M., Salesky, B., König, M. & Demuth, I. Exploring the relationship of telomere length and the epigenetic clock in the lipidcardio cohort. Int. J. Mol. Sci. 20, (2019).
24. Kuo, C. L. et al. COVID-19 severity is predicted by earlier evidence of accelerated aging. medRxiv: the preprint server for health sciences, (2020).
25. Poldi, M. C., Sies, H., Ferrucci, L. & Benzing, T. COVID-19 mortality as a fingerprint of biological age. Aging Res. Rev. 67, 101308 (2021).
26. Froidure, A. et al. Short telomeres increase the risk of severe COVID-19. Aging (Albany NY) 12, 19911–19922 (2020).
27. Hammum, G. et al. Genome-wide methylation proﬁles reveal quantitative views of human aging rates. Mol. Cell 49, 359–367 (2013).
28. Levine, M. E. et al. An epigenetic biomarker of aging for lifespan and healthspan. Aging (Albany NY) 10, 573–591 (2018).
29. Horvath, S. et al. Epigenetic clock for skin and blood cells applied to Hutchinson Gilford Progeria Syndrome and ex vivo studies. Aging (Albany NY) 10, 1758–1775 (2018).
30. Lu, A. T. et al. DNA methylation GrimAge strongly predicts lifespan and healthspan. Aging (Albany NY) 11, 303–327 (2019).
31. Bernardes, J. P. et al. Longitudinal multi-omics analyses identify responses of megakaryocytes, erythroid cells, and plasmablasts as hallmarks of severe COVID-19. Immunity 53, 1396–1414.e9 (2020).
32. Gindin, Y. et al. DNA Methylation and immune cell markers demonstrate evidence of accelerated aging in patients with chronic HBV or HCV, with or without HIV co-infection. Clin. Infect. Dis. (2020).
33. Mongelli, A. et al. Evidence for biological age acceleration and telomere shortening in COVID-19 survivors. Int. J. Mol. Sci. 22, 6151 (2021).
34. Sang, E. R., Tian, Y., Miller, L. C. & Sang, Y. Epigenetic evolution of ACE2 and IL-6 genes: non-canonical interferon-stimulated genes correlate to COVID-19 susceptibility in vertebrates. Genes (Basel) 12, (2021).
35. Liu, S. et al. Metabolic reprogramming and epigenetic changes of vital organs in SARS-CoV-2-induced systemic toxicity. JCI Insight 6, (2021).
36. Fransen, J. et al. Epigenetic clocks are not accelerated in COVID-19 patients. Int. J. Mol. Sci. 22, (2021).
37. Kuderer, N. M. et al. Clinical impact of COVID-19 on patients with cancer (CCIC99): a cohort study. Lancet 395, 1907–1918 (2020).
38. Cliff, A. K. et al. Smoking and COVID-19 outcomes: an observational and Mendelian randomisation study using the UK Biobank cohort. Thorax, (2021).
39. Leung, J. M. et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients: implications for COVID-19. Eur. Respir. J. 55, (2020).
40. Oronszy, B. et al. A review of persistent post-COVID syndrome (PPCS). Clin Rev Allergy Immunol. 1–9 (2021).
41. Yu, H. & Luo, Y. Decentered crowdfunded clinical studies-open a new era of medical research. JAMA Oncol. 5, 9–10 (2019).
42. Persson, J. et al. Monitoring the COVID-19 epidemic with nationwide telecommunication data. Proc. Natl. Acad. Sci. USA 118, (2021).
43. Xiao, C., Yi, S. & Huang, D. Genome-wide identiﬁcation of age-related CpG sites for age estimation from blood DNA of Han Chinese individuals. Electrophoresis, (2021).
44. Yu, H. et al. Novel assay for quantitative analysis of DNA methylation at single-base resolution. Clin. Chem. 65, 664–673 (2019).
51. Yang, H. S. et al. Routine laboratory blood tests predict SARS-CoV-2 infection using machine learning. *Clin. Chem.* **66**, 1396–1404 (2020).

52. Åsenius, F. et al. The DNA methylome of human sperm is distinct from blood with little evidence for tissue-consistent obesity associations. *PLoS Genet.* **16**, e1009035 (2020).

53. Zaimi, I. et al. Variation in DNA methylation of human blood over a 1-year period using the Illumina MethylationEPIC array. *Epigenetics* **13**, 1056–1071 (2019).

54. Vyas, C. M. et al. Pilot study of DNA methylation, molecular aging markers and measures of health and well-being in aging. *Transl. Psychiatry* **9**, 118 (2019).

55. Tsai, M. H. et al. S100A6 promotes B lymphocyte penetration through the blood-brain barrier in autoimmune encephalitis. *Front Genet* **10**, 1188 (2019).

56. Yeung, K. S. et al. Cell lineage-specific genome-wide DNA methylation analysis of patients with paediatric-onset systemic lupus erythematosus. *Epigenetics* **14**, 341–351 (2019).

57. Aryee, M. J. et al. Minfi: a flexible and comprehensive Bioconductor package for the analysis of Illumina DNA methylation microarrays. *Bioinformatics* **30**, 1363–1369 (2014).

58. Price, E. M. & Robinson, W. P. Adjusting for Batch Effects in DNA Methylation Microarray Data, a Lesson Learned. *Front Genet.* **9**, 83 (2018).

59. Chen, Z. et al. Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer. *J. Transl. Med.* **19**, 73 (2021).

60. Zou, Q. et al. DNA methylation-based signature of CD8 + tumor-infiltrating lymphocytes enables evaluation of immune response and prognosis in colorectal cancer. *J. Immunother. Cancer* **9**, (2021).

61. Li, X. et al. Longitudinal trajectories, correlations and mortality associations of nine biological ages across 20-years follow-up. *Elife* **9**, (2020).

62. McEwen, L. M. et al. Systematic evaluation of DNA methylation age estimation with common preprocessing methods and the Infinium MethylationEPIC BeadChip array. *Clin. Epigenetics* **10**, 123 (2018).

63. Wilk, A. J. et al. A single-cell atlas of the peripheral immune response in patients with severe COVID-19. *Nat. Med.* **26**, 1070–1076 (2020).

64. Huang, C. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *Lancet* **395**, 497–506 (2020).

65. Man, J. L., Hemani, G., Davey Smith, G., Relton, C. & Suderman, M. Meffil: efficient normalization and analysis of very large DNA methylation datasets. *Bioinformatics* **34**, 3983–3989 (2018).

Acknowledgements

This study was funded by the National Natural Science Foundation of China (81902877, HY), the Natural Science Foundation of Guangdong Province (2022A1515012656, HY; 2018A0303130303, HY), the “La Marató de TV3” Foundation (565/C/2021) to AP and ME, the Program of Introducing Talents of Discipline to Universities, and the National Key Clinical Discipline (2012).

Funding

The funding sources had no involvement in any of the study design, data collection, data analysis and interpretation, writing of the report, and decision to submit the article for publication.

Author contributions

H.Y. conceived and supervised the study; H.Y., X.C., X.W., W.L., V.D., L.P.S., A.P., and M.E. conducted data collection; V.D., L.P.S., A.P., and M.E. provided the study materials; X.C., X.W., and D.R. assisted with the collection and sorting of metadata; H.Y., T.W., and X.C. analyzed and interpreted the data; H.Y. and X.C. searched the literature and drafted the manuscript; V.D., T.W., L.P.S., A.P., M.E., W.L., D.R., and H.Y. critically revised the manuscript; All authors have approved the final manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-022-29801-8.

Correspondence and requests for materials should be addressed to Huichuan Yu.

Peer review information Nature Communications thanks Maria Cristina Polidori, and the other, anonymous, reviewer for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022